<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886180</url>
  </required_header>
  <id_info>
    <org_study_id>NGUYEN 2020-2</org_study_id>
    <nct_id>NCT04886180</nct_id>
  </id_info>
  <brief_title>Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO/ECLS): A Randomized Pilot Study ECMORIX</brief_title>
  <acronym>ECMORIX</acronym>
  <official_title>Evaluation of Oxiris Membrane as a Treatment for Ischemia-reperfusion Syndrome in Cardiogenic Shock Treated With Extracorporeal Life Support (ECMO/ECLS): A Randomized Pilot Study ECMORIX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Oxiris membrane is an AN-69 membrane whose surface is treated with polyethyleneimine&#xD;
      (PEI) grafted with heparin. This property allows the removal of lipopolysaccharide and&#xD;
      cytokines from the blood. During septic shock, this membrane has shown its effectiveness and&#xD;
      made it possible to decrease the doses of vasopressors administered, thus limiting the&#xD;
      negative consequences of their use (low mesenteric flow in particular). Moreover, the&#xD;
      literature suggests that the use of the Oxiris membrane does not lead to side effects or&#xD;
      specific and serious complications, in comparison with conventional extra-renal purification&#xD;
      membranes. To our knowledge (Pubmed, clinicaltrial) there are no data in patients in&#xD;
      cardiogenic shock assisted by ECLS.&#xD;
&#xD;
      The research hypothesis is that the early addition of an Oxiris membrane to the ECLS circuit&#xD;
      allows the removal of lipopolysaccharides and pro-inflammatory cytokines, thus controlling&#xD;
      the inflammatory cascade and limiting vasoplegia and organ failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of lipopolysaccharides</measure>
    <time_frame>24 hours after addition of the membrane</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxiris membrane</intervention_name>
    <description>Hemofiltration treatment with Oxiris membrane connected to the ECLS circuit for 24 hours.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prismaflex membrane</intervention_name>
    <description>Treatment by hemofiltration with PrismaFlex ST150 membrane connected to the ECLS circuit for 24 hours.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood tests</intervention_name>
    <description>Blood tests before and just after membrane placement and at H6, H24, H48 and H72 after membrane placement</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Trusted person or relative who has given oral consent or emergency consent&#xD;
&#xD;
          -  Person of legal age&#xD;
&#xD;
          -  Patient receiving ECLS for refractory cardiogenic shock requiring continuous renal&#xD;
             replacement therapy&#xD;
&#xD;
          -  Included within 12 hours of ECLS initiation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person not affiliated to national health insurance&#xD;
&#xD;
          -  Person under legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  Person under court order&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Severe hemorrhage under ECLS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maxime NGUYEN</last_name>
    <phone>03 80 29 35 28</phone>
    <email>maxime.nguyen-soenen@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime NGUYEN</last_name>
      <phone>03 80 29 35 28</phone>
      <email>maxime.nguyen-soenen@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

